Safety is the top priority for manufacturers of non-prescription drugs, including members of Food, Health & Consumer Products of Canada (FHCP). The well-established safety profile of acetaminophen is supported by extensive scientific research and decades of real-world use. 

FHCP is concerned that recent claims from the U.S. Administration suggesting that acetaminophen use during pregnancy or infancy can be associated with an increased risk of autism are misleading, lack broad support in the scientific community, and risk harming the general public. 

Current scientific data does not show a causal link between acetaminophen use and adverse neurodevelopmental outcomes. 

Health authorities around the world, including Health Canada, recognize acetaminophen is safe and effective when used as directed. Pregnant women should seek the advice of their healthcare professional before using acetaminophen or any other medication. 

FHCP supports continued research and promotes consumer education to help ensure the safe use of non-prescription medicines, including always reading product labels carefully, following the directions, and consulting a doctor or pharmacist before use if pregnant or breastfeeding.

FHCP also recognizes the importance of empowering Canadians with clear, evidence-based information to guide safe and effective self-care practices. FHCP and our members will work with Health Canada to ensure self-care options continue to be readily available for Canadians. 

For more information, please see the recent statements from Health Canada and the Society of Obstetricians and Gynecologists of Canada.
 
Media Contact:
Anthony Fuchs
416-648-8808
anthony.fuchs@fhcp.ca